Nearly 50% of DME patients who received an anti-VEGF drug, experienced substantial visual improvement after a year of injections.
Bressler N, Chang T, Fine J, et al. Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye: Clinical trial results from MARINA and ANCHOR. Ophthalmol. 2010; 117(4): 747-56. http://www.aaojournal.org/article/S0161-6420(09)00981-6/abstract
An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.